These preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe, and might result in long-term improvement of RCD II patients whose condition did not respond promptly to available drugs.
Introduction
Autologous Hematopoietic Stem Cell Transplantation (ASCT) is an increasingly accepted effective treatment option for patients with severe autoimmune diseases refractory to conventional treatment 1 and has been used successfully in patients with multiple sclerosis, 2 rheumatoid arthritis, 3 systemic sclerosis 4 , systemic lupus erythematosus 5 and Crohn's disease. 6 The rationale for this strategy is based on the concept of immunoablation by intense immunosuppression using high dose chemotherapy, with subsequent regeneration of naïve T lymphocytes derived from reinfused hematopoietic progenitor cells. In celiac disease (CD), HLA-DQ molecules bind and present gluten peptides to antigenspecific T-cells. These HLA-DQ-peptide complexes induce inflammatory responses in the small intestine consisting of lymphocytic infiltration of the lamina propria, expansion of the intraepithelial lymphocyte population, hyperplasia of the crypts and atrophy of the villi. 8 In a small percentage (2-5%) of celiac disease patients diagnosed as adults a refractory state develops despite strict adherence to a gluten-free diet (GFD). 9 In refractory celiac disease (RCD) the number of intraepithelial lymphocytes (IEL) is markedly raised and it is from these IEL's that enteropathy associated T cell lymphoma (EATL) may arise. 9, 10 Immunophenotyping of the IEL's identifies two groups of RCD patients: those with normal IEL's (RCD I) and those with aberrant IEL's, lacking surface expression of CD3 and CD8
(RCD II). 10, 11 RCD II can be regarded as a 'cryptic' lymphoma. 9 There is now strong molecular and immunophenotypic evidence showing that a monoclonal neoplastic T-cell population may emerge from IEL's in RCD. Clonal expansion of this monoclonal T-cell population eventually leads to frank EATL. The genesis and expansion of these monoclonal T-cells involve both inappropriate immune responses to gluten and acquisition of genetic abnormalities. Although the monoclonal IEL's in patients with RCD are neoplastic, they are not cytologically abnormal and do not form tumour masses which differentiate these patients
For personal use only. on April 6, 2017 . by guest www.bloodjournal.org From from EATL patients, in addition to the absence of radiological and bone marrow evidence of lymphoma. 10, 12, 13, 14 RCD II is usually resistant to any known therapy, including azathioprine/prednisone, cyclosporine and IL-10 therapy [15] [16] [17] [18] and has a high risk of developing EATL (60-80% within 5 years). 10, 19 This specific type of peripheral T-cell lymphomas has a very poor outcome with 1-and 5-year survival rates in the range of 31-39% and 11-20% respectively. 19, 20, 21 In a prospective multicenter study of 35 patients with EATL treated with six cycles of CHOP (Cyclophosphamide, Doxorubicine, Vincristine and Prednisone), the cumulative 2-year survival was only 28%. 11 Therefore, new treatment strategies for patients with ''premalignant'' CD (RCD-II) are urgently needed to improve their clinical condition with the ultimate goal of resetting the immune response which might prevent or delay development of overt EATL.
This study reports on the feasibility, safety and efficacy of high dose chemotherapy followed by ASCT in patients with RCD type II. coronary artery disease and heart failure (NYHA classification III) (two patients), EATL found on pre-transplantation evaluation (3 patients), and low performance status (one patient). One patient could not be treated due to unsuccessful leucopheresis; she developed EATL and died subsequently despite chemotherapy and immunotherapy with antiCD52 (Alemtuzumab).
Methods

Patients
22
The 2 patients with congestive heart failure died from: progressive disease, cachexia (one patient) and bronchiectasis (second patient). The 3 patients with EATL all died within few months, while the patient with low performance status died from cachexia. 
Inclusion criteria
Patients were only included when the diagnosis of true RCD with aberrant T cells was confirmed (except one patient (patient G) was included on the basis of extensive ulcerative jejunitis with short bowel syndrome despite having only 10% aberrant T cells), after verifying their strict adherence to a GFD, performance status according to the WHO criteria needed to be 0-2, if there was no severe concomitant cardiac, pulmonary, renal or hepatic disease.
EATL was excluded by endoscopic examination with multiple biopsies, CT-scan, PET and a trephine bone marrow biopsy. Furthermore, neither active uncontrolled infection nor HIV positivity was permitted.
Evaluation
Before proceeding to ASCT, the patients were extensively evaluated as to their performance status, the presence of concomitant diseases and extraintestinal disease or EATL. 
12,26
All flow-cytometry analyses were performed by an analyst and interpreted by the same medical immunologist, while histopathology was performed by the same pathologist to ensure uniformity, reproducibility and consistency of results.
Assessment of TCR gene rearrangement by Polymerase Chain Reaction (PCR)
T-cell receptor-gamma (TCR-γ) gene rearrangements studies were performed in separate three-four duodenal specimens that were preserved on histocon and frozen at -20°C. DNA was extracted from cryosections of duodenal specimens by a standard procedure using
For personal use only. on April 6, 2017. by guest www.bloodjournal.org From proteinase-K digestion and ethanol precipitation of the genomic DNA. TCR-γ gene rearrangements were analyzed by multiplex polymerase chain reaction (PCR) amplification under standardized conditions. A monoclonal and polyclonal control was included in each experiment. Clonality assessment for TCR-γ gene rearrangements was done using the BIOMED-2 multiplex TCR PCR protocol 12, 13, 14 .
Peripheral blood stem cells mobilization and collection
Mobilization of hematopoietic progenitor cells from the bone marrow into the peripheral blood was achieved using granulocyte-colony stimulating factor (G-CSF) 2×5 µgm/kg by subcutaneous injection for at least four days. Hematopoietic stem cells were harvested from the peripheral blood by leucapheresis and kept frozen until ASCT. The target CD34+ count was > 2× 10 6 /kg.
Conditioning and ASCT
The conditioning regimen consisted of fludarabine given orally for five days (40 mg/m 
Reinfusion of Stem Cells
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Supportive care
Patients A, C and D were supported with parenteral feeding during the two week period of oral mucositis after ASCT, while patient G was receiving parenteral nutritional support before receiving the transplant. After discharge, all patients except one (patient G) were able to be fed enterally Patient G was supported to gain weight for several months with a duodenal feeding tube and limited TPN (twice a week).
During admission, all patients received standard antibacterial and antifungal prophylaxis. 
Ethical approval and Informed consent
Approval of the medical ethics committee was obtained and all treated patients signed an informed consent. Table 1 summarizes the demographic and clinical characteristics of the patients before ASCT. The mean age at diagnosis of CD was 52.5 years (range 47-62 years) and for RCD-II was 59 years (range 51-64 years). Four patients were DQ2 homozygous and three were heterozygous. 31 The mean follow-up is 15.5 months (range 7-30 months). All patients had a WHO performance status of one except patient G (WHO performance 2). Patient G showed a remarkable clinical improvement 3-4 months after ASCT and was able to be fed partly enterally with parenteral nutritional support twice a week. 
Results
3-12-24m
Before
Before Normal range for Cyt CD3+surf CD3-% of CD103+ lymphocytes ≤ . 32 As there is no standard conditioning regimen for ASCT used in autoimmune disease 33 , a standard regimen used in our institution was used. Fludarabine induces T cell depletion while the alkylating agent melphalan was used to achieve myeloablation.
One patient was excluded due to unsuccessful leucopheresis. Although we could achieve successful leucopheresis in all patients despite earlier 2-CDA therapy, it is possible that the reason for failure of stem cell mobilization in one particular patient might be related to the use of 2-CDA. 34 T cells play an essential role in the pathogenesis of CD and RCD-II / EATL. 8, 10, 15 Through the activity of the enzyme tissue transglutaminase (tTG) glutamine residues in gluten are converted into glutamic acid. 35, 36 Subsequently a multitude of gluten-derived peptides is generated, that, when bound to either HLA-DQ2 or DQ8 can induce T-cell responses in CD patients. 8, 24 A particular glutamine and proline rich 33-mer α-gliadin peptide that contains 6 different T-cell stimulatory sequences and is resistant to gastric and duodenal proteolysis might be the primary initiator of the inflammatory response to gluten. In the large majority of patients, even in children with CD, inflammatory T-cell responses to other gluten peptides are also observed, implicating multiple gluten peptides in the disease process. 26, 27 The definition of RCD I/ II has undergone refinement in recent years. Remissions of autoimmune diseases have been described in adults after both allogenic and autologous ASCT 1-7 most probably due to the extreme immunosuppressive effects of these All our patients had negative serology before inclusion confirming their strict adherence to GFD and after ASCT all patients remained negative for anti-tTG and EMA.
Furthermore, the first 3 patients showed a significant increase in the percentage of CD8+ lymphocytes, which is seen as a marker of lymphocyte regeneration after ASCT. Although the short term results in these patients are promising, follow up at present is too short to permit firm conclusions as to efficacy. The selection of patients for this treatment should be restricted to those patients with a substantial population of aberrant T cells, even after therapy with 2-CDA who have a greater tendency to progress to highly lethal EATL.
High-dose chemotherapy followed by ASCT seems feasible and safe, and might result in long-term improvement of disease activity in RCD patients with aberrant T cells whose
For personal use only. on April 6, 2017. by guest www.bloodjournal.org From condition previously did not respond to available treatments. Longer-term follow up and additional pilot studies with larger groups of patients are needed to confirm the efficacy of this therapy.
